FDA Approves Avastin for New Second-Line Use

For patients with metastatic colorectal cancer, the Food and Drug Administration (FDA) has approved a new use of Avastin® (bevacizumab): It can be continued as part of ‘second-line’ combination therapy, even if it was used in first-line therapy. When stage IV cancer progresses despite use of Avastin plus either FOLFOX (5FU plus Eloxatin® or oxalyplatin) or FOLFIRI (5FU plus Camptosar® or…  Read More

Memorial Sloan-Kettering Will Not Offer Zaltrap

Memorial Sloan-Kettering Cancer Center made a very public announcement—and explanation—today in a New York Times op-ed about why they will not offer the new drug Zaltrap® (ziv-aflibercept) to its metastatic colorectal cancer patients. The authors, all world-renowned cancer specialists at the world’s oldest cancer center, in an op-ed headlined “In Cancer Care, Cost Matters,” essentially challenged other cancer centers…  Read More

FDA Avastin Breast Cancer Decision Doesn't Impact Colorectal Cancer Treatment

Although FDA Commissioner Margaret Hamburg announced a final decision on November 18 to drop breast cancer from the Avastin label, metastatic colorectal cancer continues to be an approved use. The Avastin® (bevacizumab) label includes the following approved indication: Metastatic colorectal cancer, with intravenous 5-fluorouracil–based chemotherapy for first- or second-line treatment. It is important to know that…  Read More

FDA: Avastin Can Cause Ovarian Failure

The FDA has changed the package insert for Avastin® (bevacizumab) to include information about newly identified risks for the drug including Loss of ovarian function (ovarian failure). Bone death in the jaw (osteonecrosis). Bleeding and additional blood clots in patients who have already had a clot in their veins while on Avastin. Changes to the Avastin…  Read More

Highlights from ASCO 2011

While there weren’t new blockbuster announcements for colorectal cancer this year at the American Society for Clinical Oncology’s (ASCO) Annual Meeting, there was plenty of focus on making what we already have work better and on choosing the patients who will benefit the most from treatments, as well as those who might not be helped at…  Read More

Leading GI Cancer Researcher Updates Patients

Last night, Dr. Edith Mitchell of Thomas Jefferson University Kimmel Cancer Center in Philadelphia, PA, updated colorectal cancer patients on the latest research and treatment news in an online webinar. Dr. Mitchell highlighted the most important news for colon and rectal cancer patients to come from the 2011 Gastrointestinal Cancers Symposium held in San Francisco last…  Read More